Follitropin
As of the edition of 20 October 2026, Follitropin is a drug: marketed, first approved in 2001 (CH); acts on FSHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Unknown
- Brand name
- Puregon
- First approved
- 14 June 2001 (CH)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Ferring Pharmaceuticals; 3 holders in all
- Registered trials
- 17, 2 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Hormones; Heart and blood vessels; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FSHR | Follicle-stimulating hormone receptor | P23945 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 5 | 2 | 0 | 2 |
| Phase 3 | 5 | 3 | 1 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Applicant | 2001 to now |
| Ferring Pharmaceuticals | Later holder | 2018 to now |